LENZ Therapeutics (LENZ) Equity Ratio (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Equity Ratio data on file, last reported at 0.9 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.9, down 5.2% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.9 (down 5.2% YoY), and the FY2025 annual result was 0.93, down 1.93% from the prior year.
• Equity Ratio fell to 0.9 in Q1 2026 per LENZ's latest filing, from 0.93 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.96 in Q3 2024 and troughed at 1.32 in Q4 2023.
• A 5-year average of 0.55 and a median of 0.93 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio sank 1654.59% in 2023, then surged 870.69% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.08 in 2022, then slumped by 1654.59% to 1.32 in 2023, then surged by 171.95% to 0.95 in 2024, then retreated by 1.93% to 0.93 in 2025, then declined by 2.71% to 0.9 in 2026.
• Business Quant data shows LENZ's Equity Ratio at 0.9 in Q1 2026, 0.93 in Q4 2025, and 0.92 in Q3 2025.